Global Epilepsy Market Insights Forecasts to 2030
- The Epilepsy Market was valued at USD 2.61 Billion in 2021.
- The Market is growing at a CAGR of 8.35% from 2022 to 2030
- The Global Epilepsy Market is expected to reach USD 4.70 Billion by 2030
- Asia Pacific is expected to grow the fastest during the forecast period
Get more details on this report -
The Global Epilepsy Market is expected to reach USD 4.70 Billion by 2030, at a CAGR of 8.35% during the forecast period 2022 to 2030.
A persistent brain condition called epilepsy is characterised by frequent, abrupt seizure occurrences. It is one of the most prevalent neurological conditions in the world, affecting individuals of all ages. Currently, there are 2.4 million new cases of epilepsy identified every year, and there are over 50 million patients living with the condition worldwide. However, the majority of cases of epilepsy are idiopathic, meaning they have no known aetiology. There is currently no cure for epilepsy; instead, only symptomatic therapy with drugs, surgery, and implantable devices is offered. This emphasises the unmet market demand for superior therapies, which would open up profitable expansion chances for business operators. The rise in accidents and brain injuries, as well as the greater risk of post-traumatic seizure occurrence in patients with brain injuries, are the primary reasons propelling the Global Epilepsy Market.
This research report categorizes the market for Epilepsy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Epilepsy market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Epilepsy market.
Global Epilepsy Market Report Coverage
|Market Size in 2021:
|USD 2.61 Billion
|Forecast Period 2021-2030 CAGR:
|2030 Value Projection:
|USD 4.70 Billion
|Historical Data for:
|No. of Pages:
|Tables, Charts & Figures:
|By Condition, By Diagnosis & Treatment, ), By End-use, By Region, and COVID-19 Impact Analysis
|LivaNova PLC, GlaxoSmithKline plc., Eisai Co., Ltd., Pfizer Inc., Medtronic, UCB S.A., NeuroPace, Inc., GW Pharmaceuticals plc., Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd, Sunovion Pharmaceuticals Inc., Sumitomo Dainippon Pharma Co. Ltd., Bausch & Lomb Incorporated, Sanofi, Takeda Pharmaceutical Company Limited., Marinus Pharmaceuticals Inc., Upsher-Smith Laboratories LLC., SK BIOPHARMACEUTICALS, Vertex Pharmaceuticals Incorporated, ESTEVE., Zogenix, Supernus Pharmaceuticals Inc, DAIICHI SANKYO COMPANY, LIMITED
|Pitfalls & Challenges:
|Covid-19 Impact Analysis
Get more details on this report -
The number of R&D dollars going into the epilepsy market is rising as a result of new trends including companies developing novel treatments for refractory epilepsy and doctors demanding more potent drugs. The market is expanding as a result of the expanding use of rational polytherapy and cutting-edge imaging technology for early diagnosis. Also, the market for epilepsy is projected to benefit from the implementation of cutting-edge digital healthcare technologies like mHealth and telemedicine. The rise in accidents and brain injuries, as well as the greater risk of post-traumatic seizure occurrence in patients with brain injuries, are the primary reasons propelling the Global Epilepsy Market. The growth of the Healthcare Epilepsy Market was also boosted by the government's increased support for research to improve and produce efficient drugs and treatments. Over 50 million individuals worldwide suffer from epilepsy, according to a World Health Organization (WHO) report, which will help the industry grow. The majority of survivors have developed epilepsy as a result of the increasing number of recorded occurrences of traffic accidents, which is driving the market. The market's main driver is the growing elderly population.
A cumbersome prescription approval process and rising drug prices are impeding the growth of demand. The epilepsy market may also be hampered by a lack of knowledge about the difficulties associated with the condition. In fact, players are increasingly requesting that social media sites and gaming firms add epileptic warnings.
- In 2021, the treatment segment is dominating the market with the largest market share over the forecast period.
On the basis of diagnosis and treatment, the global epilepsy market is segmented into diagnosis and treatment. Among these, the treatment segment is dominating the market with the largest market share over the forecast period because there are affordable drugs available to treat partial epileptic episodes. The segment's growth will also be aided by regulatory bodies' approval of effective medications. On the other hand, the diagnostic segment is predicted to mature at 9.19 percent CAGR over the evaluation period. Segment development is anticipated to be accelerated tenfold by the use of multiple imaging tests and blood testing to pinpoint the issue early on.
- In 2021, the drug resistant segment accounted the largest market share over the forecast period.
Based on the condition, the global epilepsy market is segmented into epilepsy drug-resistant/intractable epilepsy and others. Among these, the drug resistant segment holds the largest market share over the forecast period. The introduction of rational polytherapy for illness treatment with few side effects is anticipated to generate significant revenue for the epilepsy market.
- In 2021, the hospital segment is dominating the market with the largest market share over the forecast period.
On the basis of end user, the global epilepsy market is segmented into hospitals, clinics, diagnostic centers, ambulatory surgical centers, and others. Among these, the hospital segment is dominating the market with the largest market share over the forecast period due to regional government policies that prevent money from being used to upgrade the treatment centre. In the meantime, it has also been predicted that clinics, ambulatory surgical centres, and other businesses will grow at respectable rates in the years to come.
Regional Segment Analysis of the Epilepsy Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share over the forecast period.
Get more details on this report -
Due to the successful implementation of appropriate government efforts, North America leads the epilepsy market. The epilepsy market in the region will also rise over the course of the projected period as a result of the extensive research and development efforts made. Due to an increase in patient awareness regarding the active treatment of epilepsy, Asia Pacific is expected to have considerable growth in the epilepsy market. Also, it is projected that the region's epilepsy industry would rise in the upcoming years due to the rising levels of medical necessity in developing nations.
- In December 2020, to offer an instant platform for the recently acquired market-leading epilepsy drug "Buccolam" in Ireland, European CNS Specialist bought Medinutrix Ltd.
The report offers the appropriate analysis of the key organizations/companies involved within the global Epilepsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Companies
- LivaNova PLC
- GlaxoSmithKline plc.
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB S.A.
- NeuroPace, Inc.
- GW Pharmaceuticals plc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Sunovion Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Co. Ltd.
- Bausch & Lomb Incorporated
- Takeda Pharmaceutical Company Limited.
- Marinus Pharmaceuticals Inc.
- Upsher-Smith Laboratories LLC.
- SK BIOPHARMACEUTICALS
- Vertex Pharmaceuticals Incorporated
- Supernus Pharmaceuticals Inc
- DAIICHI SANKYO COMPANY, LIMITED
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global Epilepsy market based on the below-mentioned segments:
Epilepsy Market, By Condition
- Drug-resistant/intractable epilepsy
Epilepsy Market, By Diagnosis and Treatment
Epilepsy Market, By End Use
- Diagnostic centers
- Ambulatory surgical centers
Epilepsy Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?